Shots:

• The P-II clinical study involves assessing ACE-083 in FSHD patient with muscle weakness in the biceps brachii- the tibialis anterior- and a muscle in the lower leg involved in foot dorsiflexion in two parts. Part 1 study evaluates ACE-083 for 3mos. and PBO controlled Part 2 study evaluates it for 6mos. following 6mos. open-label treatment
• The P-II clinical studies resulted in improving 1EPs i.e- increase in mean total muscle volume but the increment failed to improve functional tests
• ACE-083 is a selective TGF-beta protein inhibitor that negatively regulates muscle growth with its expected results of P-II study for Charcot-Marie-Tooth disease in Q1’20

Click here to­ read full press release/ article | Ref: Acceleron Pharma | Image: Investor’s Business Daily